Precigen (PGEN) Income from Continuing Operations (2012 - 2026)
Precigen (PGEN) reported Income from Continuing Operations of 7929000.0 for Q1 2026, up 85.36% year-over-year from 4277664.57 in Q1 2025, and up 66.26% quarter-over-quarter from 23503000.0 in Q4 2025.
Precigen (PGEN) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Income from Continuing Operations data on file, last reported at 7929000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 7929000.0, up 85.36% year-over-year; the trailing twelve-month figure through Mar 2026 was 204418000.0 (down 30.49% YoY), and the FY2025 annual result was 250642000.0, down 98.55% from the prior year.
- Income from Continuing Operations advanced to 7929000.0 in Q1 2026 per PGEN's latest filing, from 23503000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 7644000.0 in Q3 2022 and troughed at 146344000.0 in Q3 2025.
- A 5-year average of 32969823.53 and a median of 23738000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations plunged 510.33% in 2025, then surged 85.36% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 22176000.0 in 2022, then plunged by 49.06% to 33056000.0 in 2023, then surged by 40.32% to 19727000.0 in 2024, then slipped by 19.14% to 23503000.0 in 2025, then soared by 66.26% to 7929000.0 in 2026.
- Business Quant data shows PGEN's Income from Continuing Operations at 7929000.0 in Q1 2026, 23503000.0 in Q4 2025, and 146344000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Precigen | 1.32 Bn | 1.32 Bn | 20.69 Mn | -7.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.93 Mn |
| Dec 31, 2025 | -23.50 Mn |
| Sep 30, 2025 | -146.34 Mn |
| Jun 30, 2025 | -26.64 Mn |
| Mar 31, 2025 | -54.15 Mn |
| Dec 31, 2024 | -19.73 Mn |
| Sep 30, 2024 | -23.98 Mn |
| Jun 30, 2024 | -58.79 Mn |
| Mar 31, 2024 | -23.74 Mn |
| Dec 31, 2023 | -33.06 Mn |
| Sep 30, 2023 | -19.80 Mn |
| Jun 30, 2023 | -20.32 Mn |
| Mar 31, 2023 | -22.73 Mn |
| Dec 31, 2022 | -22.18 Mn |
| Sep 30, 2022 | -7.64 Mn |
| Jun 30, 2022 | -26.06 Mn |
| Mar 31, 2022 | -23.90 Mn |
| Dec 31, 2021 | -26.70 Mn |
| Sep 30, 2021 | -26.32 Mn |
| Jun 30, 2021 | -30.94 Mn |